Osiris Therapeutics (NASDAQ:OSIR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, AnalystRatings.NET reports. According to Zacks, “Osiris’ third quarter loss was wider-than-expected. The company also said that certain factors impacted third quarter revenues. Although we are encouraged by […]
